Cochrane · systematic review · CD001719
Bromperidol decanoate (depot) for schizophrenia
Purgato, M, Adams, CE · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 4 · 30.8%Very low 5 · 38.5%Low 4 · 30.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsBromperidol decanoate compared to placebo for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse Bromperidol decanoate vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Global state: Hospital admission Bromperidol decanoate vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale) Bromperidol decanoate vs placebo | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, indirectness, publication bias |
Quality of life Bromperidol decanoate vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects ‐ increased weight Bromperidol decanoate vs placebo | RR 3 [0.14, 65.9] | 1 study · 20 participants | Low Downgraded: risk of bias, publication bias |
Adverse effects ‐ stiffness Bromperidol decanoate vs placebo | RR 0.25 [0.03, 1.86] | 1 study · 20 participants | Low Downgraded: risk of bias, publication bias |
Bromperidol decanoate compared to other depot antipsychotic drugs
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse Bromperidol decanoate vs other depot antipsychotic drugs | RR 3.92 [1.05, 14.6] | 2 studies · 67 participants | Low Downgraded: risk of bias, publication bias |
Global state: Hospital admission Bromperidol decanoate vs other depot antipsychotic drugs | RR 1.72 [0.7, 4.24] | 2 studies · 67 participants | Low Downgraded: risk of bias, publication bias |
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks Bromperidol decanoate vs other depot antipsychotic drugs | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, indirectness, publication bias |
Quality of life Bromperidol decanoate vs other depot antipsychotic drugs | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects ‐ needing anticholinergic drugs Bromperidol decanoate vs other depot antipsychotic drugs | RR 0.8 [0.63, 1.02] | 3 studies · 97 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |
Adverse effects ‐ anticholinergic effects Bromperidol decanoate vs other depot antipsychotic drugs | RR 3.13 [0.7, 13.95] | 1 study · 47 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |
Adverse effects ‐ movement disorders Bromperidol decanoate vs other depot antipsychotic drugs | RR 0.74 [0.47, 1.17] | 2 studies · 77 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |